Advanced Search

 

Study ID Status Title Patient Level Data
208129/034 Completed Phase III study to compare immunogenicity, safety and reactogenicity of GSK Biologicals’ novel adjuvanted hepatitis B vaccine adminstered intramuscularly, according to a 0, 6 month schedule, to Engerix™-B 20 mcg administered according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype
208129/036 Completed Study to compare the immunogenicity and safety of GSK Biologicals’ novel adjuvanted HBV vaccine (0, 21-day schedule) to a double dose of Engerix™ -B (0, 7, 21-day schedule), in pre-liver transplant patients ≥ 18 y, boosted at month 6-12
208129/037 Completed Evaluating the consistency of 3 consecutive lots of GSK Biologicals' novel adjuvanted HBV vaccine with single-blind safety evaluation using Engerix™-B as a control, administered according to a 0, 1, 2-month schedule in healthy volunteers (15-50y).
208133/161 Completed A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicals varicella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis. SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals. Study Listed on ClinicalStudyDataRequest.com
208133/178 Completed A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older. Study Listed on ClinicalStudyDataRequest.com
208136/006 Completed A phase II, open, randomized, multicentre study evaluating in healthy children 12-24 months of age, the safety and immunogenicity of GlaxoSmithKline Biologicals' combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA), compared to GlaxoSmithKline Biologicals' Varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/007 Completed Study to assess consistency of 3 production lots of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Biologicals’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life Study Listed on ClinicalStudyDataRequest.com
208136/013 Completed Study to assess immunogenicity and safety of one dose of GSK Biologicals’ live attenuated MMRV vaccine, co-administered with a booster dose of the GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine Study Listed on ClinicalStudyDataRequest.com
208136/014 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella Study Listed on ClinicalStudyDataRequest.com
208136/016 Completed Study to assess immunogenicity and safety of two lots of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Biologicals’ measles-mumps-rubella vaccine as control group Study Listed on ClinicalStudyDataRequest.com
208136/017 Completed Study to assess immunogenicity, reactogenicity and safety of a second dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age Study Listed on ClinicalStudyDataRequest.com
208136/018 Completed Study to evaluate immunogenicity and safety of GSK Biologicals’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Biologicals’ Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/019 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/022 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Biologicals' measles-mumps-rubella vaccine and varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/038 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines Study Listed on ClinicalStudyDataRequest.com
208136/039 Completed Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®. Study Listed on ClinicalStudyDataRequest.com
208136/040 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208136/041 Completed Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines Study Listed on ClinicalStudyDataRequest.com
208139/053 Completed Open, multicentric, post-marketing surveillance study of GlaxoSmithKline (GSK) Biologicals combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine (TRITANRIX-HB) injected in healthy infants according to theprescribing information Study Listed on ClinicalStudyDataRequest.com
208139/054 Completed An open randomised study in healthy infants vaccinated at birth with Engerix™-B (10µg) to evaluate the immunogenicity and the reactogenicity of the following GlaxoSmithKline (GSK) Biologicals’ vaccines: 1) combined DTP-HB vaccine (10µg HBsAg), 2) combined DTP-HB vaccine (5µg HBsAg), 3) simultaneous administration of Engerix™-B (10µg) vaccine in right thigh and whole-cell DTP vaccine in left thigh, when administered at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
208140/005p Completed Immunogenicity and reactogenicity of GSK’s DTPa-HBV vaccine and GSK’s Hib vaccine, when administered simultaneously in 2 separate injections or in one single injection, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months
208140/020 Completed Immunogenicity & reactogenicity study of GSK’s DTPa-HBV & dtpa-HBV vaccines when administered with GSK’s Hib vaccine, either mixed and given in 1 single injection or given in 2 concomitant injections, as a booster vaccination at 15 to 22 months to healthy children, previously primed with a 3 doses of DTPa-HBV
208140/032 Completed Open clinical study of the immunogenicity and reactogenicity of SB Biologicals’ DTPa-HBV vaccine, when coadministered with SB Biologicals’ Hib vaccine in 2 concomitant injections into opposite limbs, as a primary vaccination course in healthy infants aged 2, 4 and 6 months, followed by a booster at 18 months
208140/038 Completed Immunogenicity and reactogenicity study of GSK’s DTPa HBV and Hib, either mixed or given in 2 concomitant injections, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months
208141/001 Completed An open study in healthy Herpes simplex virus (HSV)-positive adults to evaluate the safety of GSK Biologicals’ candidate gD vaccine, with or without 3D MPL

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.